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In the  generation  of murine  B  cell  hybridomas secreting  immunoglobulin  (Ig) of 
defined  specificity  (1),  activated  B  lymphocytes  are  fused  with  enzyme-deficient 
variants  of terminally  differentiated  plasma  cells.  Myeloma plasma  cells  have been 
used  in  these  experiments  to  facilitate  the  construction  of hybrid  cells  with  the 
characteristic  of secreting large amounts  of Ig.  Fortunately,  the available  library  of 
murine  plasmacytomas  is  large  and  a  number  of appropriately  adapted  murine 
plasma cell lines exist. In the human, the available number of terminally differentiated 
plasma cells that  grow well  in vitro is more restricted,  and only a  few myeloma cell 
lines  have been  fused  in  the  hypoxanthine-aminopterin-thymidine  (HAT)  selection 
system with limited success (2, 3). This paucity of human myeloma lines has prompted 
investigators to construct interspecies hybridomas between rodent myeloma cell lines 
and human B cells (4). However, the ability to transform human B cells with Epstein- 
Barr  virus  (EBV)  has  resulted  in  a  large  number  of B  cell  lines  (BCL)  at  various 
stages of B cell differentiation. In general, these lines are not terminally differentiated, 
express surface membrane Ig, and secrete small quantities orig. In the studies reported 
below, several chemically mutagenized HGPRTase-deficient variants of human EBV- 
transformed  cell  lines  were selected  and  used  for the  construction  of human  B  cell 
hybridomas producing Ig. These experiments show that such lines function effectively 
as parental tumor partners in fusion studies. The resultant hybridomas allow for both 
the synthesis and secretion of antigen-specific Ig. 
Materials  and Methods 
Isolation and Stimulation  of Normal  B  Lymphocytes.  T  and B cell fractions were obtained from 
mononuclear cell (MNC) suspensions of peripheral venous blood and tonsillar or splenic tissue 
by the  sheep  erythrocyte rosetting  technique.  1 ×  106 B  cells  were  cultured  with  2  ×  l0  s 
irradiated  (1,500  rad)  T  cells  and  pokeweed  mitogen  (PWM)  (1:100;  Gibco Laboratories, 
Grand  Island,  NY)  in  2 cc of RPMI  1640 medium  (M.  A. Bioproducts, Walkersville,  MD) 
supplemented  with  10%  fetal  bovine serum  (Reheis Chemical Co.,  Phoenix, AZ). After 5  7 
days, cells were harvested, washed twice in RPMI 1640 medium, and fused. 
HGPRTase-deficient  Human B  Cell Lines.  The enzyme-deficient EBV-transformed line GM 
0467 (5) was obtained from the Human Genetic Mutant Cell Repository, Institute for Medical 
Research, Camden, NJ. The 8-azaguanine-resistant subclone of WI-L2 (6), AG  ~t 35scl  (7), was 
a gift from Dr. A. S. Tung of the Merck Institute for Therapeutic Research. These lines were 
subcloned  further  in  semisolid  agarose in  the  presence of 20 /lg/ml  of 8-azaguanine over a 
monolayer of HGPRTase-deficient  human  fibroblasts  (GM  152). Clones were picked under 
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microscopic visualization after 8-12 d of growth and maintained in RPMI 1640 with 10% fetal 
bovine serum (FBS) and 20/~g/ml of 8-azaguanine. Two selected subclones, WI-L2 AG  ~ 35sc 1.1 
(herein called H35.1.1) and 0467.3, were used in the fusion experiments reported below. 
Cell Fusion Techniques and Conditions  for Growth of Hybrid Cells.  PWM-stimulated human B cell 
blasts  were  fused  with  HGPRTase-deficient  human  B  cell  line  cells  in  the  presence  of 
polyethylene glycol (PEG)  (~ 1,000 tool wt; J. T. Baker Chemical Co., Phillipsburg, N  J) by a 
modification of the technique of Kennett et al. (8).  1 ×  107 mitogen-stimulated B cell blasts 
and an equal number of B cell line cells were incubated at room temperature with 0.5 ml of 
40%  PEG for 2 rain with continuous swirling and then centrifuged for 6  rain at  1,800  rpm. 
After washing in RPMI  1640 medium, 1 ×  105 cells were dispensed in complete medium into 
tissue culture plates (Linbro Chemical Co.,  Hamden,  CT).  Complete medium consisted of 
RPMI 1640 (75%), NCTC-109 (10%), FBS (15%), penicillin (100 U/ml), streptomycin (100/~g/ 
ml), kanacycin sulfate (50/~g/ml), hypoxanthine (10  -4 M), thymidine (5  ×  10  -n M), bovine 
insulin (0.2 U/ml), and oxaloacetie acid (10 -a M). 24 h later, 0.1 ml of aminopterin (10 -7 M) 
was added to each well. All wells were fed every 3 d for 3-6 wk with a similar concentration of 
aminopterin in complete medium. Wells were then scored as to growth of cells, and supernatants 
were screened for Ig production as described below. 
Detection of Ig Production. Synthesis of Ig was determined by indirect intracytoplasmic immu- 
nofluorescence on fixed hybrid cell preparations using monoclonal murine antibodies to human 
~, )~,/L, and  y  chains  (provided by Dr. J.  D.  Capra, University of Texas,  Dallas, TX)  and 
rhodamine-labeled rabbit anti-mouse antibodies. A modification of the enzyme-linked immu- 
nosorbent assay (ELISA) reported by Giallongo et al. (9) was used to determine Ig secretion. 
Specific anti-tetanus  toxoid  antibodies were  detected  by  a  direct  binding  assay  in  which 
hybridoma culture supernatants or known quantities of affinity-purified, polyclonal, human 
anti-tetanus antibodies were incubated  for  1 h  at  37°C  with  plates (Nunc  Immuno  Plates, 
Vanguard  International, Neptune,  N  J)  coated with  10/~g/ml  of tetanus toxoid (or tetanus 
toxin), washed extensively and then exposed to a  pool of affinity-purified, peroxidase-labeled 
goat antibodies to human ~ and X chains (Tago, Inc., Burlingame, CA) for 1 h at 37°C. After 
further washing, the assay was developed with an appropriate substrate (9),  and the optical 
densities at  490  nrn  were  determined.  Quantitations  of the  amounts  of Ig  secreted  were 
determined by constructing a standard curve using the results obtained with various dilutions 
of purified human  anti-tetanus antibodies. Nonspecific Ig secretion was  quantitated by an 
inhibition assay in which the affinity-purified, peroxidase-labeled goat antibodies specific for 
K and ;k were blocked from binding to human  Ig-coated plates by either hybridoma culture 
supernatants or culture medium containing known amounts of human myeloma proteins of the 
appropriate light chain type. 
Results 
Construction of lg-producing Human B Cell Hybridomas Using HGPRTase-deficient  Human 
B  Cell Lines.  Two  representative  human  BCL  are  described in  these experiments. 
These  are  selected  EBV-transformed  progeny  of a  spleen  cell  from  a  patient  with 
hereditary spherocytosis  (H35.1.1)  and  a  peripheral blood cell from  a  patient  with 
mononucleosis  (0467.3).  The  former is a  mutagenized,  HGPRTase-deficient variant 
(7) of the WI-L2 line (6), the latter an enzyme-deficient variant (5) of the PGLC33H 
line.  Both  of these  lines have  been  cloned  before and  several times  after chemical 
mutagenesis. The H35.1.1  clone expresses •  light chains on the surface membrane of 
1-2%  of the  cells during  log phase  growth  and  contains  only  1-2%/~  ~  producing 
plasmacytoid cells. 0467.3 expresses  1-3% surface IgM 7~ bearing cells with  13-21% # 
containing plasma cells. H35.1.1  and 0467.3  produce -1-50  ng/ml of Ig in a  48-h 
culture period as quantitated by the ELISA inhibition assay described above. 
In a  series of experiments, PWM-activated peripheral blood, tonsillar, or splenic B 
lymphocytes were fused with these BCL in the presence of PEG. After fusion, 105 cells 
were  dispensed into wells and  cultured  in  HAT  selection medium  (10)  for 3-6 wk. 
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TABLE  I 
Construction of lg-producing Human B Cell Hybridomas Using an HGPRTase-deficient  Human B 
Cell Line 
Percent of growth-positive wells 
EBV-trans-  Source of PWM-stimu-  Percent of growth-posi-  synthesizing:* 
formed B cell  tive wells after HAT  lated normal B cells 
line  selection 
i¢ chains  ~ chains 
H35.1.1  --  --  2.1  <0.0l 
H35.1.1  Peripheral blood  14.9  (64/428)  13.0  8.0 
H35.1.1  Spleen  22.1  (168/760)  49.0~c  21.0:~ 
H35.1.1  Tonsil  18.2  (36/192)  18  10 
* Synthesis of either I¢ or 2~ light chains was determined by intracellular immunofluorescence on fixed cells from various 
growth-positive wells. Wells were scored as positive for lg synthesis if 10% or more of the cells contained large amounts 
of light chain. 
Jg Only the first  100 growth-positive wells were assayed for intracellular Ig. 
activated B cells from three anatomic sources. In these experiments, from 14.9-22.1% 
of the wells initially cultured were positive for growth after HAT selection. Although 
fusions were obtained with B lymphocytes from all three sources, there is a suggestion 
that B cells from solid tissues (spleen and tonsil) fuse more efficiently. This observation 
has been true for B cell fusions with several other parental BCL. To determine the 
percent of growth-positive wells synthesizing Ig, aliquots of each culture were stained 
for the presence of large amounts of intracytoplasmic light or heavy chain production. 
Because the parental  line  H35.1.1  contains  negligible numbers of plasma  cells, all 
cultures with >10% plasma cells were scored as positive for Ig synthesis. As listed in 
Table I, between 21 and 70% of the growth-positive wells were found to contain cells 
with large amounts of intracellular light chain. Many cultures contained from 50 to 
100% mature plasma cells. Immunofluorescent staining for heavy chains demonstrated 
that >90% of the cells were producing IgM, usually of only one light chain type. In 
addition, selected growth positive cultures negative for Ig secretion were proven to be 
hybrids by the coexpression of both parental HLA-Dr alleles on the same cells and by 
chromosomal hyperploidy. 
Fig.  1 illustrates the amounts of Ig secreted by the hybridomas produced from a 
fusion between 0467.3 and PWM-stimulated tonsillar B lymphocytes. In this experi- 
ment, 21% of the wells were growth positive (21/100) and 91% of these (19/21) were 
found to contain cells with large quantities of human Ig.  13 Ig-synthesizing cultures 
were chosen at random and analyzed for Ig secretion by the ELISA inhibition assay. 
12 of the 13 cultures secreted between 0.1 and 5.0/zg/ml of Ig as compared with ~50 
ng/ml in the parental line 0467.3 grown under similar conditions. An evaluation of 
the light chains secreted by these cultures suggested that in several instances secretion 
of the parental IgM ~ was lost. Furthermore, this implies that the cultures were clonal 
at this stage. Analysis of heavy chain production showed that  17 of the  19 cultures 
were synthesizing IgM and 2 of the 19 made IgG. 
Secretion of Specific Human Anti-Tetanus  Toxoid Antibodies by a Human  B  Cell Hybridoma. 
Because the B  cells used  for the fusion shown  in  Fig.  1 came from the tonsils of a 
donor who had received a tetanus toxoid booster immunization 1 wk before tonsillec- 
tomy,  the  supernatants  of the  Ig-producing  fusions  were  assayed  for  anti-tetanus 
toxoid binding activity. One culture was found that produced 400 ng/ml of specific 
antibody. This antibody was found to bind also to tetanus toxin but not to diphtheria 
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Fxo.  1.  Concentrations  of  •  and  h  Ig  present  in  13  randomly  chosen  growth-positive  wells  from 
fusion  of  PWM-activated  human  tonsillar  B  cells  with  0467.3  line.  Data  were  obtained  using 
inhibition of anti-K or anti-~ binding to human Ig-coated wells. Known concentrations of human  Fr 
II  were  used  to  construct  a  standard  inhibition  curve  against  which  culture  supernatants  were 
compared. 
TABLE  II 
Marker Characteristics of Anti-Tetanus  Toxoid Antibody-secreting Human Hybridomas 
Percent cells staining on surface  Percent cells staining intracellularly 
i  a  7  K  h  /t  y  ~  h 
Specific anti- 
tetanus anti- 
body secreted 
ttglml 
0467.3  2  --  --  1.3  13  --  21  <0.001 
TT1  (uncloned)  78  --  --  70  28  --  32  0.40 
"Iq'l. 1  35  --  --  31  81  --  --  83  1.6 
TTI.2  21  --  --  26  >95  --  --  >95  2.8 
TT1.7  >95  --  --  >95  >95  --  --  >95  1.8 
TTI.8  >95  --  --  >95  >95  --  --  >95  1.3 
x4  --  18  23  --  --  50  54  --  <0.001 
in vitro for 9  mo, was cloned by limiting dilution  technique in medium containing 
50%  human fibroblast culture supernatant.  After  14 d, 38%  of the wells plated were 
secreting detectable amounts of tetanus toxoid specific antibody. The fastest dividing 
of these clones were saved. Table II lists a comparison of the marker characteristics of 
four of the clones, the parental line 0467.3, the uncloned hybridoma TT 1 and another 
hybridoma from the same fusion secreting an irrelevant IgG x (x4). Clones TT 1.1 and 
1.2 appear similar, with 20-30% of the cells expressing IgM h on their surface and 80- 
95%  of the cells containing large amounts of intracellular  Ig.  Clones TT1.7  and  1.8 
have  a  much  higher  percentage  of  surface  staining  cells  (~95%)  with  a  similar 
percentage of plasma cells. Whether these cells represent fusions of distinct cell types 
within  the  initial  growth-positive  well  or  rather  variants  with  different  growth 
characteristics is unclear.  However, it is clear that the clones show a  marked enrich- 
ment for plasma cells and anti-tetanus antibody production as compared to the parent 
TT1. 
Because the TT1 clones secreted Ig specific for tetanus toxoid, attempts were made 
to  demonstrate  surface  expression  of  these  same  antibodies.  In  cytofluorographic 
analysis,  37.9%  of the hybrid cells bound fluorescein-labeled  tetanus toxoid as com- 
pared with <1%  of the parental  line cells 0467.3.  A  9-channel  peak shift  suggested 
that more cells were actually binding the fluorochrome-labeled tetanus toxoid antigen. 934  CHIORAZZI ET  AL.  BRIEF  DEFINITIVE REPORT 
Discussion 
These data demonstrate that EBV-transformed BCL function effectively as fusion 
partners  for  the  construction  of Ig-producing  human  B  cell  hybridomas.  Using 
primarily two HGPRTase-deficient BCL (H35.1.1 and 0467.3), ~20% of the cultures 
plated were positive for growth after HAT selection. From 10 to 90% of these growth- 
positive wells synthesized new Ig. One culture produced human antibody specific for 
tetanus toxoid and  tetanus toxin. This was cloned by limiting dilution into several 
subclones,  shown  to secrete  large  quantities  of specific antibody and  also  to  bind 
fluorochrome-labeled antigen, presumably by membrane-associated Ig. Proof of cell 
hybridization was provided by growth  in selective media, the presence of intact Ig 
production, frequently of a  light chain type not expressed by the parental line, the 
coexpression of both parental HLA-Dr antigens, and karyotypic analyses. 
The enzyme-deficient EBV lines reported here were especially convenient for fusion 
studies since they could be cloned efficiently. Most EBV-transformed B cell cultures 
clone inefficiently in  their initial  state.  However, during the chemical  mutagenesis 
procedure selection for cloning ability is made. The variants obtained and the hybrids 
constructed retain this growth characteristic. 
Synthesis  and  secretion  of new  Ig  by  the  hybridomas  were  easily  detected  by 
comparing either the total number of intracellular Ig-positive cells or the amounts of 
Ig  produced.  The  uncloned  hybridomas  constructed  with  these  lines  frequently 
contained 50-100% plasma cells as determined by intracytoplasmic immunofluores- 
cence. In addition, these lines secreted from 0.01  to 5.0 #g/ml of antibody after 48 h 
culture. This suggests that  the differentiation stage of the parental  tumor line does 
not dictate the differentiation stage of the resultant hybridoma. Although several IgG- 
producing hybridomas  have been  found,  the  dominant  isotype produced  by these 
hybridomas is  IgM.  It  is  unclear at  this stage  whether this relates to the parental 
tumor lines or to the subset or differentiation state of the PWM-activated normal B 
cells. During this study, considerable work was carried out with two plasma cell lines, 
including one previously described (2), after eradication of mycoplasma. After fusion, 
many of these hybridomas actually showed a decrease in,the number of plasma cells 
by fluorescence analyses with anti-Ig reagents, just the reverse of what was observed 
for  the  EBV  lines.  However,  some  successful  Ig-producing  fusion  products  were 
obtained and the relative merits of the two types of parental lines awaits further study. 
In  addition  to the production of anti-tetanus  antibody by fused cells from EBV 
lines,  the synthesis of antibodies with  rheumatoid  factor activity have been  found 
that express a major cross-reactive idiotypic determinant (11). Furthermore, a number 
of other antibody-secreting hybridoma systems are currently under detailed analysis, 
including those for anti-nuclear antibodies from cells of patients with systemic lupus 
erythematosus and for antibodies to allergens from cells of allergic patients. 
Thus, the work with the two lines described above, as well as with others obtained 
by EBV transformation not  discussed in this report, suggests that  these are general 
properties of EBV lines. Indeed, one of the lines from a  myeloma patient previously 
described  as  effective in  human  B  cell  hybridization  (3)  was  found  to  show  the 
presence of EBV nuclear antigen. Because EBV lines are easily generated and many 
are already available for chemical mutagenesis,  it should not prove too difficult to 
obtain parental lines for human B cell hybridization studies. CHIORAZZI ET AL.  BRIEF DEFINITIVE REPORT  935 
Summary 
HGPRTase-deficient  EBV-transformed  B  cell  lines  were  shown  to  be  effective 
fusion  partners  with  mitogen-activated  human  B  cells  for  the  construction  of Ig- 
producing human B cell hybridomas. In a  series of experiments using these lines and 
B  cells  from  several  tissue  sources,  ~20%  of the  cultures  plated  were  consistently 
positive for growth after hypoxanthine-aminopterin-thymidine selection and ~30% of 
these synthesized significant new Ig. A  marked  increase in Ig secretion was observed 
after hybridization, which was due to new Ig; Ig from the parental  line was shown to 
disappear in several instances.  Special analyses were carried out on a  human hybrid- 
oma  secreting  antibody  specific  for  tetanus  toxoid and  tetanus  toxin  and  stable 
subclones were derived.  These studies suggest that EBV-transformed lines will prove 
useful  in  human  hybridization  studies,  thus  making  a  large  library  of B  cell  lines 
available for the generation of human monoclonal antibodies. 
Assays for the detection of EBV nuclear antigen were performed by Dr. Warren Andiman of 
Yale University School of Medicine.  The fluorescein-labeled  tetanus  toxoid was a  gift from 
David Fisher.  The authors appreciate the technical assistance of Alice Mayer and Ruth Brooks. 
Received  for publication 17June 1982. 
References 
1.  K~Jhler, G., and C. Milstein.  1975. Continuous cultures of fused cells secreting antibody of 
predefined specificity.  Nature (Lond.).  256:495, 
2.  Olsson, L., and H. S.  Kaplan.  1980. Human-human hybridomas producing monoclonal 
antibodies of predefined antigenic specificity.  Proc. Natl.  Acad. Sci. U. S. A. 77:5429. 
3.  Croce, C. M., A. Linnenbach, W. Hall, Z. Steplewski,  and H. Koprowski. 1980. Production 
of human hybridomas secreting antibody to measles  virus. Nature (Lond.).  288:488. 
4.  Lane, H. C., J. H. Shelhamer, H. S. Mostowski, and A. S. Fauci. 1982. Human monoclonal 
anti-KLH antibody-secreting hybridoma produced from peripheral blood B lymphocytes 
of a KLH-immune individual.].  Exp. Med.  155:333. 
5.  Sato,  K.,  R.  S.  Slesinski,  and  J.  W.  Littlefield.  1972. Chemical  mutagenesis  at  the 
phosphoribosyhransferase  locus  in  cultured  human  lymphoblasts.  Proc. Natl.  Acad. Sci. 
U. S. A. 69:1244. 
6.  Levy, J.  A.,  M.  Virolainen,  and  V.  Defendi.  1968. Human  lymphoblastoid  lines  from 
lymph node and spleen.  Cancer. 22:517. 
7.  Lever, J. E., G. Nuki, and J. E. Seegmiller.  1974. Expression of purine overproduction in a 
series of 8-azaguanine-resistant diploid human lymphoblast lines. Proc. Natl.  Acad. Sci.  U. S. 
A. 71:2679. 
8.  Kennett, R. H., K. A. Denis, A. S. Tung, and N. R. Klinman. 1978. Hybrid plasmacytoma 
production: fusions with adult spleen cells, monoclonal spleen fragments, neonatal spleen 
cells and human spleen cells. Curr. Top. Microbiol. Immunol. 81:77. 
9.  Giallongo, A., L. Kochoumian, and T. P. King. 1982. Enzyme- and radioimmunoassays for 
specific murine IgE and IgG with different solid-phase immunosorbents.J. ImmunoL Methods. 
In press. 
10.  Szybalski, W., E. H. Szybalski, and G. Ragni.  1962. Genetic studies with human cell lines. 
Natl.  Cancer Inst.  Monogr. 7:75. 
11.  Bonagura, V. R., H. G. Kunkel, and B. Pernis.  1982. Cellular localization of rheumatoid 
factor idiotypes. J.  Clin. Invest. 69:1356. 